Navigation Links
Congenital rubella syndrome nearly eradicated in the US

Congenital rubella syndrome, a birth defect caused by the rubella virus (also known as German measles), has practically been eliminated in the U.S., according to a statement published in the April 2006 issue of Birth Defects Research Part A, the official journal of The Teratology Society. The journal is available online via Wiley InterScience at http://www3.interscience.wiley.com/cgi-bin/jhome/102526943.

Endorsed by the Teratology Society, the Organization of Teratology Information Specialists (OTIS), the Neurobehavioral Teratology Society, and the Behavioral Toxicology Society, the statement notes that rubella is no longer an endemic disease in this country and congenital rubella syndrome "is almost a thing of the past in the United States." Birth defects resulting from rubella may include blindness, deafness, and congenital heart disease. A rubella epidemic in the early 1960s caused more than 11,000 fetal deaths and 20,000 infants to be born with congenital rubella syndrome, but a more effective vaccine introduced in the 1970s has helped in eliminating transmission of rubella from expectant mothers to their unborn babies.

"Effectively, congenital rubella syndrome has been nearly eradicated from the United States," according to the statement. There were fewer than 10 cases or rubella reported in the U.S. last year and in the past 5 years there have only been 4 cases of congenital rubella syndrome reported, only one of which was in a child whose mother had been born in the U.S.

The remarkable success of the immunization program to eliminate rubella is due to joint efforts by the Centers for Disease Control and Prevention, various state and local health departments, the American Academy of Pediatrics, the American College of Obstetrics and Gynecology, and the March of Dimes, according to the statement. Maintaining high rubella immunization rates is crucial to the continue d success of these efforts. The statement concludes: "Effective strategies, such as continued universal childhood and adolescent immunization, must be secured to extend this success worldwide."


'"/>

Source:John Wiley & Sons, Inc.


Related biology news :

1. 15-year hunt finds cause of pseudothalidomide syndrome
2. Gene for immune deficiency syndromes found
3. Removing DNA repair gene causes metabolic syndrome
4. Researchers link two more genes to sudden infant death syndrome
5. Down syndrome: Its not just the age factor
6. A potential biological cause for sudden infant death syndrome
7. Drug treatment improves learning in mice with Down syndrome symptoms, Stanford/Packard study shows
8. Angelman syndrome deficits rescued in mice
9. Chronic fatigue syndrome impairs a persons slow wave activity during sleep
10. New research says winning a Nobel Prize adds nearly 2 years to your lifespan
11. Breast tumors in mice eradicated using cancer vaccine
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/22/2016)... , November 22, 2016 According to the new ... Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function ... by MarketsandMarkets, the market is expected to grow from USD 10.74 Billion ... of 16.79% between 2016 and 2022. Continue ... ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
(Date:11/15/2016)... Research and Markets has announced the addition of the "Bioinformatics ... ... The global bioinformatics market is projected ... in 2016, growing at a CAGR of 21.1% during the forecast ... by the growing demand for nucleic acid and protein sequencing, increasing ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... 8, 2016 Eutilex Co. Ltd. today announced ... $18.9M) Series A financing. This financing round included participation ... and SNU Bio Angel. This new funding brings the ... (US $27.7M) since its founding in 2015. ... development and commercialization of its immuno-oncology programs, expand its ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA ... dose escalation and expansion clinical trial for its lead drug candidate, AC0010, at ... of the trial was to determine the safety, antitumor activity, and recommended phase ...
(Date:12/7/2016)... LANSING, Mich. , Dec. 7, 2016 ... it has named Dr. Dan Kephart as ... the company. Kephart will assume his responsibilities at Neogen ... research and development director for the agribusiness unit of ... food safety development at Life Technologies. His extensive industry ...
(Date:12/7/2016)... 2016  Nordion, a standalone business of Sterigenics ... today,s award by the United States Department of ... the Phase II cooperative agreement funding to GA ... University of Missouri Research Reactor Center (MURR ® ... establishment of a new, reliable supply of molybdenum ...
Breaking Biology Technology: